Skip to NavigationSkip to content


NICE recommends Novo's liraglutide for management of obesity and non-diabetic hyperglycaemia

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made available via the NHS for patients in England and Wales for the management of obesity and non-diabetic hyperglycaemia.

The recommendation relates to patients with a body mass index of at least 35 kg per square metre with a high risk of cardiovascular disease. The therapy is to be prescribed in secondary care and will be administered alongside exercise and a reduced-calorie diet.

FDA approves Novo Nordisk's Victoza for children with type 2 diabetes

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes.

The drug is the first non-insulin drug approved to treat paediatric patients with type 2 diabetes since metformin was approved in 2000.

The injectable diabetes drug has however been available to adult patients since 2010.

Weight loss drug reduces diabetes risk by 80%, according to ICL research

Researchers from Imperial College London have published research showing that use of weight loss drug liraglutide lowered the risk of developing type 2 diabetes by 80% versus placebo.

The team observed the effects of the drug in 2,254 patients with ‘borderline diabetes’ or ‘prediabetes’, a state of increased blood sugar levels which affects around 10% of people in the UK and leads to diabetes in up to 10% of sufferers within 10 years. The research was conducted across 191 sites in 27 countries.

Novo Nordisk presents positive long-term results for Saxenda

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the drug demonstrated greater weight loss and improvements in cardiometabolic risk factors, compared with placebo.

As early as 16 weeks, 68% of people treated with Saxenda were early responders, with many losing 5% of more of their body weight by this time. Of these early responders, an average weight loss of 8.6% had occurred by week 160, compared to 2.9% with placebo.

Jardiance scores more cardiovascular outcomes data

Boehringer Ingelheim and Lilly co-market Jardiance for type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug reduces the risk of heart failure outcomes by 39%.

Earlier this year the two companies in the diabetes alliance presented preliminary data from the EMPA-REG OUTCOMES trial, which was the first to find that a blood sugar-lowering drug could reduce the risk of cardiovascular events.

Novo Nordisk obesity drug is launched in the US

Novo image

Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients.

Saxanda (liraglutide) is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management and was approved in the country late last year.

The drug should accompany a regime of physical activity and a low-calorie diet for obese adults who have at least one weight-related condition including type 2 diabetes, or high cholesterol.

Novo Nordisk obesity drug gets EU approval

Saxenda image

Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU.

This approval follows a nod from the EMA in January and approval by the FDA in December. It allows the drug to be used in patients who have an initial body mass index (BMI) of more than 27 kg/m2 and at least one other weight-related problem ­– such as hypertension, dyslipidaemia or obstructive sleep apnoea.

Novo Nordisk obesity drug gets FDA nod

Novo image

The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight management. 

In addition to a regime of physical activity and a low-calorie diet, Saxenda (liraglutide) is approved for use in obese adults who have at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. 

Novo's diabetes drug Victoza approved in China

Novo Nordisk's type II diabetes drug Victoza (liraglutide)
Novo Nordisk expects to launch Victoza (liraglutide) in China in the second half of this year

Novo Nordisk’s injectable diabetes drug Victoza has been given regulatory approval in China.

The Chinese State Food and Drug Administration (SFDA) granted it a licence as an add-on to metformin or sulfonylurea in people with type II diabetes.

Diabetes is a rapidly growing disease in China, the manufacturer says, and it expects to launch Victoza (liraglutide)there in the second half of the year.

Diabetes drugs show promise in Alzheimer's

Novo Nordisk's Victoza
Novo Nordisk’s Victoza (liraglutide) was one of two drugs used in the study

Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease.

Researchers at the University of Ulster in Coleraine funded by research charity the Alzheimer’s Research Trust, studied the effects of two drugs – Novo Nordisk’s Victoza (liraglutide) and Lilly’s Byetta (exenatide) - as part of an investigation into the link between diabetes and Alzheimer’s disease.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches